BioSpace News Archive

Cerebral palsy is the most common childhood physical disability in the United States and throughout the world.

Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company) today announced recent activity, new positive data and expected near term milestones across its clinical development pipeline.

SQZ Biotechnologies Company (NYSE: SQZ), focused on unlocking the full potential of cell therapies, today reported full year 2022 financial results and recent portfolio updates.

SQZ Biotechnologies Company (NYSE: SQZ), focused on unlocking the full potential of cell therapies, today announced that, according to RECIST 1.1 criteria, a confirmed complete response was observed in the first patient in the lowest-dose cohort of the Phase 1 SQZ-AAC-HPV-101 clinical trial.

ERYTECH Pharma (Nasdaq & Euronext: ERYP) today provided a business and financial update for the fourth quarter and full year of 2022.

ScreenPro Security Inc. (CSE: SCRN) OTCQB: SCRSF) (“ScreenPro” or the “Company”) is pleased to announce the appointment of Alexander G. MacKay as its new Chief Executive Officer (CEO) and Chairman of the Company, effective March 23, 2023.

Eisai Co., Ltd. announced the company will present the latest findings on lecanemab, Eisai’s anti-amyloid beta protofibril* antibody for the treatment of Alzheimer’s disease, at the 2023 International Conference on Alzheimer’s and Parkinson’s Diseases and related neurological disorders from March 28-April 1 in Gothenburg, Sweden and virtually.

Ionis announced the outcome of the U.S. Food and Drug Administration’s Peripheral and Central Nervous System Drugs Advisory Committee meeting on tofersen, an investigational antisense medicine for the treatment of people with superoxide dismutase 1 amyotrophic lateral sclerosis.